Relative Intelligence · Medical Devices

How Abbott Laboratories (ABT) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on ABT alone. It places ABT (Abbott Laboratories) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where ABT stands in the market, and of the alternatives worth a closer look.
Period covered: ABT's full trading record, from October 1986 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowThe slide is ABT's own: it is 23.9% below its high, against 1.3% for the S&P 500. Not every peer went the same way. Over the past 3 months, ISRG (Intuitive Surgical) rose 24.0% and COO (Cooper Companies) fell 17.4%. Consistency ↓
- Stock or market?ABT rose 1.6% over the past 3 months, 5.8 points behind the medical devices ETF IHI (iShares U.S. Medical Devices ETF), which rose 7.5%. The S&P 500 rose 3.9%. Its medical device peers did not move as one over the past 3 months: ISRG (Intuitive Surgical) rose 24.0%, while COO (Cooper Companies) fell 17.4%.
- Past 1 to 3 yearsOver the past year, ABT fell 18.7% while the S&P 500 rose 15.8%. The same gap shows up over 3 years (13.0% against 89.3%). By year ↓
- Long termABT turned $10,000 into $30,400 over the past decade, against $42,100 in the S&P 500. Growth of $10,000 ↓
- In a crashABT fell less than the S&P 500 in five of seven sell-offs, but the 2022 bear market broke the pattern: it fell 27.9%, more than the S&P 500's 24.5%. Crash tests ↓
- DiversificationWhen the S&P 500 had a down month, ABT usually fell with it (18 of 22 months). On the flip side, about 16% of ABT's month-to-month variation tracks the S&P 500. The rest is its own. That is mostly its own path. By year ↓
- Better options
- Popular alternatives
- JNJ (Johnson & Johnson) earned more than ABT with less volatility over the past 5 years: 12.7% a year at 17.9% volatility, against a loss of 1.7% a year at 23.1%.
- Nearby categories and themes
- NVS (Novartis, pharmaceuticals) and TAK (Takeda Pharmaceutical, pharmaceuticals) earned more than ABT with less volatility over the past 5 years. NVS returned 17.1% a year at 20.7% volatility, against a loss of 1.7% a year at 23.1%.
- Whole market
- 901 of the 3,633 stocks and funds worth at least $500 million earned more than ABT with less volatility over the past 5 years, among them VTI (Vanguard Morningstar Total Stock Market ETF), VOO (Vanguard S&P 500 ETF) and BRK-B (Berkshire Hathaway).
How much would $10,000 in ABT have grown?
This chart tracks a hypothetical $10,000 investment in ABT over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of ABT over the same span and ABT's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in ABT at the end of September 1997 would have grown to $130,278 by September 2026, less than the $132,907 it would have become in SPY, an S&P 500 fund.
- Six of the eight other investments on the chart ended ahead of ABT, and RMD finished highest, at $1,650,038.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 440 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of ABT; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- RMD$2M+16,400% total · +19.3% a year
- DHR$777,394+7,674% total · +16.2% a year
- LLY$396,376+3,864% total · +13.5% a year
- SYK$323,233+3,132% total · +12.7% a year
- TMO$235,386+2,254% total · +11.5% a year
- JNJ$189,226+1,792% total · +10.7% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
- ABT$130,278+1,203% total · +9.3% a year
- CVS$97,705+877% total · +8.2% a year
- MDT$61,200+512% total · +6.4% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,725 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of ABT; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- LLY$52,411+424% total · +39.3% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- JNJ$18,849+88.5% total · +13.5% a year
- ISRG$12,270+22.7% total · +4.2% a year
- TMO$11,986+19.9% total · +3.7% a year
- CVS$11,915+19.1% total · +3.6% a year
- SYK$11,008+10.1% total · +1.9% a year
- ABT$9,221−7.8% total · −1.6% a year
- RMD$8,780−12.2% total · −2.6% a year
- DHR$8,422−15.8% total · −3.4% a year
ABT at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- ABT is still 23.9% below its all-time high.
- ABT's deepest decline since it began trading in 1986 was 45.7%, from January to July 2002. It took about four years from the low to climb back to its old high.
- Over 29 full calendar years, ABT's best was 2017, when it returned 52.0%, and its worst was 2002, when it lost 26.8%. It lost money in seven of those years.
The company
- Market value
- $178B
- Industry
- Medical - Devices
- Price history from
- October 1986
Returns
- Past 1 year
- −18.7%total return
- Past 3 years
- +13.0%+4.2% a year
- Past 5 years
- −8.0%−1.7% a year
- Past 10 years
- +204%+11.8% a year
- Best calendar year
- +52.0%2017
- Worst calendar year
- −26.8%2002
- Losing years
- 7 of 29full calendar years
Risk
- Volatility
- 23.1%typical yearly swing, 5 years
- Sharpe ratio
- 0.04return per unit of risk, 5 years
- Worst decline ever
- −45.7%Jan 2002 to Jul 2002
- From its all-time high
- −23.9%below the peak
ABT against the whole market
Where ABT ranks among every stock and fund, and what across the market has done better.
How does ABT rank among all stocks?
This section ranks ABT on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how ABT stacks up against its peers, these rankings show where it stands in the market as a whole.
- ABT's worst decline of the past 10 years ranks in the top 7% of the 2,187 stocks worth at least $300 million, where the top fell the least.
- ABT's 1-year return ranks in the bottom 21% of the 3,287 stocks worth at least $300 million with 1 year of history.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | ABT | Rank | Standing |
|---|---|---|---|
| 1-year return | −18.7% | 2,610 of 3,287 | bottom 22% |
| 3-year return | +13.0% | 2,121 of 3,017 | bottom 31% |
| 5-year return | −8.0% | 1,834 of 2,893 | bottom 38% |
| 10-year return | +204% | 847 of 2,202 | top 38% |
| Volatility, 5 years | 23.1% | 218 of 2,893 | top 8% |
| Sharpe ratio, 5 years | 0.04 | 2,248 of 2,893 | bottom 23% |
| Worst decline, past 10 years | −39.6% | 145 of 2,187 | top 7% |
What has beaten ABT on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). ABT sits where the dashed lines cross. Anything in the green box above and to the left earned more than ABT with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 107 stocks and 794 ETFs worth at least $500 million sit in the green region: each earned more than ABT over the past 5 years with smaller price swings. That is 25% of the 3,633 screened.
- Among those with at least half ABT's swings, DXJ has the best return for its risk: 26.6% a year at 19.1% volatility, 17% less than ABT's 23.1%, and a Sharpe ratio (return above cash per unit of volatility) of 1.34 against 0.04 for ABT.
- Among ABT's popular alternatives, JNJ is in the region. JNJ earned 12.7% a year against a loss of 1.7% a year for ABT, at 17.9% volatility, 22% less than ABT's 23.1%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to ABT; faint dots are 92 more of the 901 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than ABT?
Investments that beat ABT over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among ABT's popular alternatives, JNJ earned more than ABT with less volatility over the past 5 years: 12.7% a year at 17.9% volatility, against a loss of 1.7% a year at 23.1%.
- Looking beyond its popular alternatives, NVS (pharmaceuticals) and TAK (pharmaceuticals) earned more than ABT with less volatility over the past 5 years. NVS returned 17.1% a year at 20.7% volatility, against a loss of 1.7% a year at 23.1%.
- Across the whole market, 901 of the 3,633 stocks and funds worth at least $500 million earned more than ABT with less volatility over the past 5 years, among them VTI, VOO and BRK-B.
How this works
The table below lists investments that beat ABT over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks ABT's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than ABT follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than ABT's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× ABT's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than ABT's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with ABT?lower diversifies more | Expenseper year | |||
| −1.7% | 23.1% | 0.04 | −39.6% | +204% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.39 | 0.09% | |||
| Popular alternativesbest 6 shownThe investments people most often weigh against ABT. 7 of 23 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.47 | — | ||
| Higher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.26 | — | ||
| Higher return in most periods | +2.9% | 27.8% | 0.24 | −40.9% | +366% | 0.36 | — | ||
| Higher return in most periods | +5.2% | 34.6% | 0.32 | −49.9% | +478% | 0.44 | — | ||
| Higher return in most periods | +5.3% | 30.4% | 0.32 | −56.8% | +47.0% | 0.43 | — | ||
| Higher return, similar volatility | +2.3% | 24.1% | 0.22 | −39.9% | +71.4% | 0.42 | — | ||
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Medical Devices and the categories next to it (Health Care Facilities, Pharmaceuticals, Life Sciences Tools, Health Care Distribution), plus ABT's specific themes. 25 of 55 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.56 | — | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.57 | — | ||
| Higher return, similar volatilityHigher return in most periodsSmaller losses in recent crashes | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.31 | — | ||
| Higher return, lower volatilityHigher return in most periods | +11.9% | 19.4% | 0.68 | −54.4% | +30.4% | 0.27 | — | ||
| On the frontierHigher return, similar volatilityHigher return in most periods | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.36 | — | ||
| Higher Sharpe, smaller worst decline | +0.6% | 25.3% | 0.15 | −33.5% | +61.5% | 0.38 | — | ||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,449 of 3,555 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.22 | 0.40% | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.39 | 0.03% | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.57 | — | ||
LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.54 | 0.40% | |
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +5.1% | 18.3% | 0.37 | −23.8% | +145% | 0.45 | — | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.24 | — | ||
| Similar return, lower volatility | −1.7% | 11.3% | -0.10 | −19.4% | — | 0.18 | — | ||
ERIEErie Indemnity Company · Property & Casualty Insurance | Smaller losses in recent crashes | +6.3% | 31.4% | 0.35 | −60.9% | +200% | 0.30 | — | |
What these numbers mean for ABT
- Annual return
- ABT lost 1.7% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $9,200. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- ABT's volatility over the past 5 years was 23.1%, 1.3 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, ABT's return lands within 23.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- ABT's Sharpe ratio over the past 5 years was 0.04, against 0.79 for the S&P 500, so ABT earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- ABT's worst fall from a peak to a low over the past 10 years was 39.6%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 39.6% fall takes a 65.7% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, ABT's monthly returns had a correlation of 0.39 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against ABT instead: the lower it is, the more that option would diversify a ABT holding. Guide: Correlation and diversification →
Show all 901 stocks and funds worth at least $500 million that earned more than ABT with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with ABT | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.22 | 0.40% | |
| 2 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.39 | 0.03% | |
| 3 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.57 | — | |
| 4 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.54 | 0.40% |
| 5 | Whole market | +5.1% | 18.3% | 0.37 | −23.8% | +145% | 0.45 | — | |
| 6 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.58 | 0.04% | |
| 7 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.53 | 0.06% | |
| 8 | Whole market | +11.7% | 21.8% | 0.62 | −32.7% | +416% | 0.24 | 0.18% | |
| 9 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.44 | 0.06% | |
| 10 | Whole market | +11.4% | 17.0% | 0.72 | −23.1% | — | 0.44 | 0.21% | |
| 11 | Whole market | +13.9% | 18.5% | 0.80 | −34.0% | +446% | 0.61 | — | |
| 12 | Whole market | +5.5% | 21.5% | 0.36 | −30.1% | +89.8% | 0.52 | — | |
| 13 | PJULInnovator U.S. Equity Power Buffer ETF · Broad Market | Whole market | +10.5% | 8.6% | 1.20 | −18.2% | — | 0.42 | 0.79% |
| 14 | FJANFT Vest U.S. Equity Buffer ETF - January · Multi-Asset | Whole market | +11.1% | 10.5% | 1.05 | −13.6% | — | 0.34 | 0.85% |
| 15 | Whole market | +7.2% | 19.2% | 0.46 | −29.0% | +68.8% | 0.39 | — | |
| 16 | Whole market | +5.4% | 21.8% | 0.35 | −34.3% | +240% | 0.55 | — | |
| 17 | Whole market | +11.4% | 17.3% | 0.71 | −34.1% | +293% | 0.46 | 0.15% | |
| 18 | Whole market | +7.5% | 11.0% | 0.71 | −13.7% | — | 0.64 | 0.35% | |
| 19 | Whole market | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.66 | 0.08% | |
| 20 | CHTChunghwa Telecom Co., Ltd. · Integrated Telecommunications | Whole market | +7.7% | 13.3% | 0.63 | −23.8% | +101% | 0.22 | — |
| 21 | SPMOInvesco S&P 500 Momentum ETF · US Momentum Equity | Whole market | +18.7% | 20.8% | 0.93 | −30.9% | +499% | 0.22 | 0.13% |
| 22 | IUSGiShares Core S&P U.S. Growth ETF · US Growth Equity | Whole market | +12.9% | 21.2% | 0.68 | −32.4% | +405% | 0.26 | 0.04% |
| 23 | DFIVDimensional - International Value ETF · International Equity | Whole market | +14.8% | 16.4% | 0.93 | −25.4% | — | 0.52 | 0.27% |
| 24 | AVLVAvantis U.S. Large Cap Value ETF · US Large-Cap Value | Whole market | +14.0% | 16.9% | 0.86 | −19.5% | — | 0.43 | 0.15% |
| 25 | Same or nearby category | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.56 | — | |
| 26 | USMViShares MSCI USA Min Vol Factor ETF · US Low-Volatility Equity | Whole market | +7.6% | 12.3% | 0.66 | −33.1% | +176% | 0.66 | 0.15% |
| 27 | EWJiShares MSCI Japan ETF · International Equity | Whole market | +9.2% | 18.8% | 0.57 | −33.1% | +132% | 0.38 | 0.49% |
| 28 | BUFRFT Vest Laddered Buffer ETF · Buffered Equity | Whole market | +9.9% | 10.5% | 0.96 | −13.7% | — | 0.41 | 0.10% |
| 29 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.40 | — | |
| 30 | CHDChurch & Dwight Co., Inc. · Household & Personal Products | Whole market | +6.1% | 21.1% | 0.39 | −31.7% | +154% | 0.36 | — |
| 31 | IOOiShares Global 100 ETF · Global Equity | Whole market | +15.7% | 17.2% | 0.94 | −31.4% | +361% | 0.35 | 0.40% |
| 32 | XLGInvesco S&P 500 Top 50 ETF · US Large-Cap Equity | Whole market | +13.8% | 18.9% | 0.78 | −30.5% | +379% | 0.27 | 0.20% |
| 33 | ESGVVanguard ESG U.S. Stock ETF · US ESG Equity | Whole market | +11.3% | 18.5% | 0.67 | −33.7% | — | 0.37 | 0.09% |
| 34 | JQUAJPMorgan U.S. Quality Factor ETF · US Quality Equity | Whole market | +13.6% | 15.7% | 0.89 | −32.9% | — | 0.50 | 0.12% |
| 35 | DIVOAmplify CWP Enhanced Dividend Income ETF · Equity Income | Whole market | +11.1% | 11.9% | 0.95 | −30.0% | — | 0.60 | 0.56% |
| 36 | XLPState Street Consumer Staples Select Sector SPDR ETF · Consumer Staples | Whole market | +7.2% | 13.8% | 0.57 | −24.5% | +121% | 0.56 | 0.08% |
| 37 | Popular alternative | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.47 | — | |
| 38 | MOATVanEck Morningstar Wide Moat ETF · US Large-Cap Equity | Whole market | +9.1% | 18.4% | 0.57 | −33.3% | +276% | 0.53 | 0.46% |
| 39 | JAVAJPMorgan Active Value ETF · US Large-Cap Value | Whole market | +11.5% | 14.5% | 0.82 | −16.5% | — | — | 0.44% |
| 40 | Whole market | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.12 | 0.09% | |
| 41 | QYLDGlobal X - Nasdaq 100 Covered Call ETF · Equity Income | Whole market | +8.4% | 15.0% | 0.62 | −24.7% | +156% | 0.24 | 0.60% |
| 42 | DBMFiMGP DBi Managed Futures Strategy ETF · Alternatives | Whole market | +9.8% | 12.4% | 0.82 | −20.4% | — | -0.21 | 0.85% |
| 43 | USMCPrincipal U.S. Mega-Cap ETF · Broad Market | Whole market | +14.1% | 16.4% | 0.89 | −30.0% | — | 0.41 | 0.12% |
| 44 | FTCSFirst Trust Capital Strength ETF · US Quality Equity | Whole market | +6.2% | 13.2% | 0.52 | −31.9% | +188% | 0.68 | 0.53% |
| 45 | VIGIVanguard International Dividend Appreciation ETF · International Equity | Whole market | +4.9% | 14.5% | 0.40 | −31.0% | +122% | 0.64 | 0.07% |
| 46 | TDIVFirst Trust NASDAQ Technology Dividend Index Fund · Technology Equity | Whole market | +16.2% | 21.3% | 0.81 | −32.0% | +388% | 0.22 | 0.50% |
| 47 | Whole market | +23.5% | 18.8% | 1.22 | −75.2% | +350% | 0.38 | — | |
| 48 | FTLSFirst Trust Long/Short Equity ETF · Broad Market | Whole market | +10.2% | 10.4% | 0.99 | −20.6% | +158% | 0.47 | 0.95% |
| 49 | OMFLInvesco Russell 1000 Dynamic Multifactor ETF · US Multifactor Equity | Whole market | +9.0% | 16.4% | 0.61 | −33.2% | — | 0.46 | 0.29% |
| 50 | PTLCPacer Trendpilot US Large Cap ETF · Broad Market | Whole market | +9.5% | 11.8% | 0.83 | −26.6% | +188% | 0.38 | 0.60% |
| 51 | SPUSSP Funds S&P 500 Sharia Industry Exclusions ETF · Technology | Whole market | +15.0% | 19.5% | 0.82 | −30.8% | — | 0.28 | 0.45% |
| 52 | XYLDGlobal X - S&P 500 Covered Call ETF · International | Whole market | +7.4% | 11.2% | 0.70 | −33.4% | +128% | 0.40 | 0.60% |
| 53 | EQWLInvesco S&P 100 Equal Weight ETF · Broad Market | Whole market | +11.6% | 15.0% | 0.81 | −34.3% | +291% | 0.53 | 0.30% |
| 54 | BCIabrdn Bloomberg All Commodity Strategy K-1 Free ETF · Alternatives | Whole market | +10.1% | 16.7% | 0.66 | −32.7% | — | 0.00 | 0.26% |
| 55 | ACWViShares MSCI Global Min Vol Factor ETF · International | Whole market | +6.3% | 10.3% | 0.65 | −28.8% | +116% | 0.71 | 0.20% |
| 56 | ACIOAptus Collared Income Opportunity ETF · Dividend & Income | Whole market | +9.3% | 11.1% | 0.86 | −14.2% | — | 0.38 | 0.79% |
| 57 | FTHIFirst Trust BuyWrite Income ETF · Dividend & Income | Whole market | +10.3% | 13.3% | 0.81 | −32.7% | +126% | 0.38 | 0.75% |
| 58 | SCHYSchwab International Dividend Equity ETF · International | Whole market | +9.5% | 13.3% | 0.75 | −24.0% | — | 0.58 | 0.08% |
| 59 | FLQLFranklin U.S. Large Cap Multifactor Index ETF · Broad Market | Whole market | +13.8% | 16.3% | 0.88 | −33.6% | — | 0.39 | 0.15% |
| 60 | FHLCFidelity MSCI Health Care Index ETF · Healthcare | Whole market | +7.3% | 15.4% | 0.53 | −28.8% | +199% | 0.65 | 0.08% |
| 61 | XTiShares Future Exponential Technologies ETF · Broad Market | Whole market | +7.3% | 21.2% | 0.44 | −34.4% | +279% | 0.28 | 0.46% |
| 62 | AVIVAvantis International Large Cap Value ETF · International | Whole market | +12.6% | 16.7% | 0.80 | −27.7% | — | 0.53 | 0.25% |
| 63 | DSTLDistillate U.S. Fundamental Stability & Value ETF · Broad Market | Whole market | +11.3% | 16.1% | 0.75 | −33.1% | — | 0.66 | 0.39% |
| 64 | JAAAJanus Henderson AAA CLO ETF · CLO Bonds | Whole market | +5.1% | 1.7% | 2.98 | −2.6% | — | 0.13 | 0.20% |
| 65 | RLYState Street Multi-Asset Real Return ETF · Multi-Asset | Whole market | +9.9% | 13.3% | 0.78 | −34.2% | +128% | 0.38 | 0.50% |
| 66 | RAAXVanEck Real Assets ETF · Commodities | Whole market | +11.7% | 15.6% | 0.79 | −33.9% | — | 0.33 | 0.55% |
| 67 | INFLHorizon Kinetics Inflation Beneficiaries ETF · Broad Market | Whole market | +11.8% | 17.8% | 0.72 | −21.3% | — | 0.47 | 0.85% |
| 68 | FDLOFidelity Low Volatility Factor ETF · Broad Market | Whole market | +9.8% | 13.0% | 0.79 | −34.4% | +249% | 0.57 | 0.15% |
| 69 | QGROAmerican Century U.S. Quality Growth ETF · Broad Market | Whole market | +9.9% | 21.2% | 0.55 | −32.6% | — | 0.43 | 0.29% |
| 70 | DBJPXtrackers MSCI Japan Hedged Equity ETF · International | Whole market | +20.9% | 19.2% | 1.09 | −31.3% | +348% | 0.15 | 0.45% |
| 71 | PPHVanEck Pharmaceutical ETF · Healthcare | Whole market | +11.6% | 15.8% | 0.78 | −29.7% | +153% | 0.60 | 0.36% |
| 72 | PTNQPacer Trendpilot 100 ETF · Technology | Whole market | +9.7% | 14.1% | 0.73 | −28.1% | +305% | 0.06 | 0.65% |
| 73 | FTXHFirst Trust Nasdaq Pharmaceuticals ETF · Healthcare | Whole market | +11.9% | 16.9% | 0.75 | −32.1% | +153% | 0.53 | 0.60% |
| 74 | HLALWahed FTSE USA Shariah ETF · Broad Market | Whole market | +14.0% | 18.0% | 0.82 | −33.6% | — | 0.27 | 0.50% |
| 75 | EQLALPS Equal Sector Weight ETF · Broad Market | Whole market | +13.5% | 14.5% | 0.94 | −34.2% | +387% | 0.55 | 0.19% |
| 76 | QQEWFirst Trust Nasdaq-100 Select Equal Weight ETF · Technology | Whole market | +6.8% | 21.3% | 0.42 | −32.1% | +267% | 0.36 | 0.55% |
| 77 | FLSPFranklin Systematic Style Premia ETF · Alternatives | Whole market | +8.4% | 13.4% | 0.68 | −22.9% | — | 0.18 | 0.65% |
| 78 | SIXHETC 6 Meridian Hedged Equity Index Option ETF · Broad Market | Whole market | +10.2% | 10.2% | 1.00 | −11.7% | — | 0.54 | 0.31% |
| 79 | IDHQInvesco S&P International Developed Quality ETF · International | Whole market | +10.0% | 17.9% | 0.63 | −33.6% | +183% | 0.50 | 0.29% |
| 80 | QQQEDirexion NASDAQ-100 Equal Weighted Index ETF · Broad Market | Whole market | +8.1% | 20.7% | 0.48 | −32.1% | +294% | 0.33 | 0.35% |
| 81 | DGTState Street SPDR Global Dow ETF · International | Whole market | +13.8% | 15.1% | 0.94 | −34.4% | +261% | 0.52 | 0.50% |
| 82 | DXJWisdomTree Japan Hedged Equity Fund · International Equity | Whole market | +26.6% | 19.1% | 1.34 | −39.1% | +428% | 0.19 | 0.48% |
| 83 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.52 | — | |
| 84 | OUSAALPS Funds O’Shares U.S. Quality Dividend ETF · Dividend & Income | Whole market | +9.4% | 13.4% | 0.74 | −33.1% | +186% | 0.67 | 0.48% |
| 85 | VSLUApplied Finance Valuation Large Cap ETF · Broad Market | Whole market | +13.7% | 16.2% | 0.88 | −23.8% | — | 0.46 | 0.49% |
| 86 | WTPIWisdomTree Equity Premium Income Fund · Alternatives | Whole market | +9.1% | 12.2% | 0.78 | −28.4% | +121% | 0.41 | 0.44% |
| 87 | SSUSStrategy Shares Day Hagan Smart Sector ETF · Broad Market | Whole market | +10.5% | 15.4% | 0.73 | −23.8% | — | 0.34 | 0.77% |
| 88 | RSPHInvesco S&P 500 Equal Weight Health Care ETF · Healthcare | Whole market | +6.1% | 16.8% | 0.44 | −30.4% | +177% | 0.67 | 0.40% |
| 89 | Whole market | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.37 | — | |
| 90 | SVOLSimplify Volatility Premium ETF · Dividend & Income | Whole market | +7.6% | 21.8% | 0.44 | −33.5% | — | 0.41 | 0.66% |
| 91 | Whole market | +15.7% | 20.4% | 0.82 | −42.6% | +248% | 0.48 | — | |
| 92 | Whole market | +17.8% | 21.4% | 0.88 | −53.7% | +140% | 0.23 | — | |
| 93 | Whole market | +13.6% | 21.4% | 0.71 | −51.0% | +295% | 0.37 | — | |
| 94 | Whole market | +12.9% | 19.9% | 0.71 | −46.9% | +187% | 0.44 | — | |
| 95 | BALTInnovator Defined Wealth Shield ETF · Crypto | Whole market | +6.3% | 3.3% | 1.85 | −4.9% | — | 0.39 | 0.69% |
| 96 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | 0.38 | — | |
| 97 | VRIGInvesco Variable Rate Investment Grade ETF · Bonds | Whole market | +4.7% | 1.3% | 3.51 | −13.1% | +40.5% | 0.15 | 0.30% |
| 98 | Whole market | +14.7% | 17.5% | 0.87 | −34.7% | — | 0.39 | 0.26% | |
| 99 | FLRTPacer Aristotle Pacific Floating Rate High Income ETF · Financials | Whole market | +6.0% | 2.3% | 2.55 | −21.0% | +58.0% | 0.22 | 0.60% |
| 100 | Whole market | +4.4% | 20.9% | 0.31 | −35.8% | +245% | 0.67 | — |
ABT against its popular alternatives
The investments people most often weigh against ABT, compared period by period and year by year.
How do ABT's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at ABT, which divides the map into what did better or worse on each measure.
- Only JNJ was both more rewarding and calmer than ABT over the past 5 years, earning a higher annual return with lower volatility.
- 13 of the 23 popular alternatives earned less than ABT over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, ABT returned -1.7% a year, less than the S&P 500's 12.7%, with higher volatility (23.1% against 17.1%).
Green points earned more than ABT with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| LLY Eli Lilly and Company | +40.7% | 32.8% |
| JNJ Johnson & Johnson | +12.7% | 17.9% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| CVS CVS Health Corp. | +5.3% | 30.4% |
| ISRG Intuitive Surgical, Inc. | +5.2% | 34.6% |
| SYK Stryker Corporation | +3.2% | 25.7% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| BDX Becton, Dickinson and Company | +2.3% | 24.1% |
| BSX Boston Scientific Corporation | +0.5% | 26.6% |
| RMD ResMed Inc. | −0.4% | 31.8% |
| ABT This pageAbbott Laboratories | −1.7% | 23.1% |
| MDT Medtronic Plc | −1.8% | 22.5% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| NVO Novo Nordisk A/S | −4.0% | 39.1% |
| EW Edwards Lifesciences Corporation | −5.3% | 32.7% |
| PHG Koninklijke Philips N.V. | −6.8% | 38.0% |
| ICUI ICU Medical, Inc. | −7.0% | 40.0% |
| ZBH Zimmer Biomet Holdings, Inc. | −7.2% | 27.2% |
| DXCM DexCom, Inc. | −9.2% | 47.3% |
| COO The Cooper Companies, Inc. | −10.4% | 30.4% |
| PODD Insulet Corp. | −13.7% | 44.1% |
| TFX Teleflex Incorporated | −18.2% | 34.5% |
| BAX Baxter International Inc. | −19.8% | 34.9% |
| ALGN Align Technology, Inc. | −24.4% | 50.0% |
| TNDM Tandem Diabetes Care, Inc. | −33.5% | 69.0% |
Has ABT consistently beaten its popular alternatives?
This section compares ABT with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than ABT helps separate lasting outperformance from a single strong stretch.
- Six of the 24 popular alternatives, led by LLY, TMO and RMD, outperformed ABT in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- LLY, TMO and RMD outperformed ABT in every long-term period and in all but one short-term period, the most consistent record in the group.
- LLY and JNJ earned more for the risk they took than ABT (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than ABT over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| ABT Abbott Laboratories (this page) | — | +0.3% | +1.6% | +8.4% | −15.3% | −18.7% | +13.0% | −8.0% | +204% | 23.1% | 0.04 | −39.6% | — | $178B | — |
| LLY QualifiedEli Lilly and Company | 5/5 short3/3 longAll-weather | +10.2% | +12.1% | +40.0% | +19.4% | +59.7% | +124% | +451% | +1,807% | 32.8% | 1.21 | −34.5% | — | $1.2T | — |
| TMO QualifiedThermo Fisher Scientific Inc. | 5/5 short3/3 longAll-weather | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| RMD QualifiedResMed Inc. | 5/5 short3/3 longAll-weather | +9.8% | +24.0% | +9.2% | +1.1% | −8.6% | +75.3% | −1.7% | +331% | 31.8% | 0.15 | −54.0% | — | $35B | — |
| ISRG QualifiedIntuitive Surgical, Inc. | 3/5 short3/3 long | +9.0% | +24.0% | −5.9% | −22.1% | −4.5% | +64.1% | +28.9% | +478% | 34.6% | 0.32 | −49.9% | — | $155B | — |
| JNJ QualifiedJohnson & Johnson | 4/5 short2/3 long | −3.8% | +4.8% | +13.6% | +27.1% | +36.9% | +84.6% | +82.1% | +196% | 17.9% | 0.76 | −27.4% | — | $625B | — |
| CVS QualifiedCVS Health Corp. | 4/5 short2/3 long | +8.2% | −11.4% | +25.6% | +21.0% | +18.5% | +52.5% | +29.2% | +47.0% | 30.4% | 0.32 | −56.8% | — | $121B | — |
| SYK Medical - DevicesStryker Corporation | 2/5 short2/3 long | +11.4% | −4.3% | −9.5% | −11.8% | −19.2% | +18.0% | +17.2% | +197% | 25.7% | 0.25 | −43.8% | — | $117B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 5/5 short1/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| BDX Medical - Instruments & SuppliesBecton, Dickinson and Company | 5/5 short1/3 long | +7.2% | +26.2% | +23.7% | +28.9% | +32.3% | +1.6% | +12.2% | +71.4% | 24.1% | 0.22 | −39.9% | — | $53B | — |
| MDT Medical - DevicesMedtronic Plc | 5/5 short1/3 long | +4.0% | +14.5% | +13.3% | +1.0% | +1.9% | +43.6% | −8.8% | +46.7% | 22.5% | 0.03 | −45.1% | — | $121B | — |
| ICUI Medical - Instruments & SuppliesICU Medical, Inc. | 5/5 short1/3 long | +3.8% | +2.4% | +23.4% | +16.3% | +37.3% | +49.0% | −30.5% | +12.5% | 40.0% | 0.02 | −73.8% | — | $4.0B | — |
| DXCM Medical - DevicesDexCom, Inc. | 4/5 short1/3 long | −3.8% | +13.3% | +32.7% | +28.9% | +25.3% | −0.3% | −38.4% | +316% | 47.3% | 0.04 | −66.3% | — | $32B | — |
| EW Medical - DevicesEdwards Lifesciences Corporation | 3/5 short1/3 long | −0.1% | +3.9% | +8.4% | +3.5% | +17.3% | +27.1% | −23.6% | +125% | 32.7% | 0.01 | −54.3% | — | $51B | — |
| PHG Medical - DevicesKoninklijke Philips N.V. | 3/5 short1/3 long | +4.4% | −2.8% | −8.0% | −0.2% | −5.1% | +65.1% | −29.5% | +31.7% | 38.0% | 0.00 | −77.9% | — | $25B | — |
| BSX Medical - DevicesBoston Scientific Corporation | 2/5 short1/3 long | +4.3% | +4.1% | −25.3% | −51.9% | −54.7% | −8.9% | +2.5% | +98.1% | 26.6% | 0.15 | −61.6% | — | $66B | — |
| PODD Medical - DevicesInsulet Corp. | 1/5 short1/3 long | +1.5% | −14.8% | −29.0% | −49.6% | −56.4% | −1.4% | −52.2% | +255% | 44.1% | -0.12 | −63.0% | — | $9.9B | — |
| BAX Medical - Instruments & SuppliesBaxter International Inc. | 5/5 short0/3 long | +6.9% | +11.1% | +30.2% | +25.9% | +6.2% | −20.7% | −66.7% | −40.7% | 34.9% | -0.45 | −81.2% | — | $13B | — |
| ZBH Medical - DevicesZimmer Biomet Holdings, Inc. | 4/5 short0/3 long | +2.1% | +7.3% | +1.1% | +7.5% | −5.6% | −5.5% | −31.1% | −16.1% | 27.2% | -0.14 | −52.1% | — | $18B | — |
| ALGN Medical - DevicesAlign Technology, Inc. | 3/5 short0/3 long | +2.5% | −14.0% | −21.5% | −3.5% | +11.5% | −44.2% | −75.3% | +64.4% | 50.0% | -0.30 | −82.9% | — | $11B | — |
| TFX Medical - Instruments & SuppliesTeleflex Incorporated | 3/5 short0/3 long | +5.1% | −1.9% | −0.1% | +8.0% | +1.6% | −28.1% | −63.4% | −17.4% | 34.5% | -0.41 | −76.7% | — | $5.6B | — |
| GEHC Medical - DevicesGE HealthCare Technologies Inc. | 3/5 short0/3 long | +8.4% | +11.8% | −5.2% | −15.1% | −6.8% | +10.1% | — | — | — | — | −37.4% | — | $32B | — |
| COO Medical - Instruments & SuppliesThe Cooper Companies, Inc. | 1/5 short0/3 long | +9.2% | −17.4% | −14.9% | −27.1% | −21.2% | −27.1% | −42.3% | +32.5% | 30.4% | -0.21 | −53.2% | — | $11B | — |
| TNDM Medical - DevicesTandem Diabetes Care, Inc. | 1/5 short0/3 long | −6.2% | −8.7% | −22.2% | −23.3% | +6.3% | −14.5% | −87.0% | −76.4% | 69.0% | -0.25 | −96.8% | — | $1.1B | — |
| NVO Drug Manufacturers - GeneralNovo Nordisk A/S | 0/5 short0/3 long | −1.1% | −20.0% | −1.5% | −23.9% | −28.5% | −57.0% | −18.5% | +134% | 39.1% | 0.09 | −75.2% | — | $174B | — |
How did ABT do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where ABT ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with ABT and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- ABT finished ahead of the S&P 500 in 14 of its 29 full calendar years, and behind it in each of the last four.
- Among its popular alternatives, ISRG came out ahead of ABT most often, in 17 of the 25 years both traded.
- Ranked against its popular alternatives each year, ABT finished in the top quarter in five of 29 years and in the bottom quarter in five. In 2025, it ranked 6 of 25.
Newest year first. Green marks a year in which the fund came out ahead of ABT; gray means the two finished within a fraction of a point. The rank row places ABT among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of ABT | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT This pageAbbott Laboratories | — | +12.9% | +4.8% | +2.3% | −20.7% | +30.5% | +28.1% | +22.1% | +29.1% | +52.0% | −12.3% | +1.9% | +20.1% | +24.3% | +20.3% | +21.8% | −8.3% | +4.6% | −2.5% | +18.1% | +26.9% | −13.5% | +9.2% | +19.3% | −26.8% | +17.0% | +35.8% | −24.7% | +51.9% | +31.4% |
| Rank among alternatives | Top quarter in 5 of 29 | 6 of 25 | 10 of 25 | 12 of 25 | 14 of 24 | 10 of 24 | 10 of 24 | 20 of 24 | 8 of 24 | 6 of 24 | 20 of 24 | 15 of 24 | 15 of 24 | 16 of 23 | 12 of 23 | 5 of 23 | 18 of 23 | 22 of 23 | 2 of 23 | 10 of 22 | 6 of 22 | 17 of 21 | 15 of 21 | 14 of 21 | 15 of 21 | 8 of 18 | 12 of 16 | 13 of 16 | 5 of 16 | 11 of 16 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 15 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| LLY Eli Lilly and Company | 17 of 29 | +40.3% | +33.3% | +60.9% | +34.3% | +66.1% | +31.0% | +16.2% | +40.5% | +17.8% | −10.4% | +25.4% | +39.8% | +7.3% | +24.2% | +25.2% | +3.6% | −6.2% | −21.3% | +5.7% | −5.2% | +2.6% | −17.6% | +13.1% | −17.6% | −14.4% | +41.9% | −24.3% | +29.1% | +93.6% |
| TMO Thermo Fisher Scientific Inc. | 18 of 29 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% | −11.4% | −61.5% | +6.7% |
| RMD ResMed Inc. | 18 of 29 | +6.3% | +34.2% | −16.5% | −19.5% | +23.4% | +38.3% | +37.8% | +36.4% | +39.1% | +18.0% | −2.3% | +21.7% | +15.3% | +65.1% | −26.7% | +32.5% | +39.4% | −28.6% | +6.8% | +28.4% | +50.0% | +23.0% | +35.9% | −43.3% | +35.2% | +91.2% | −7.9% | +222% | +27.2% |
| ISRG Intuitive Surgical, Inc. | 17 of 25 | +8.5% | +54.7% | +27.1% | −26.2% | +31.8% | +38.4% | +23.4% | +31.2% | +72.7% | +16.1% | +3.3% | +37.7% | −21.7% | +5.9% | +79.6% | −15.0% | +139% | −60.7% | +237% | −18.2% | +193% | +134% | +38.7% | −38.6% | +18.0% | — | — | — | — |
| JNJ Johnson & Johnson | 11 of 29 | +47.5% | −4.8% | −8.6% | +6.0% | +11.4% | +10.8% | +16.2% | −5.1% | +24.4% | +15.3% | +1.2% | +17.3% | +34.6% | +10.8% | +9.9% | −0.6% | +11.3% | −7.7% | +3.6% | +12.4% | −3.4% | +25.2% | −2.0% | −7.9% | +14.0% | +14.2% | +12.5% | +29.0% | +34.3% |
| CVS CVS Health Corp. | 16 of 29 | +84.3% | −40.8% | −12.6% | −7.6% | +54.9% | −5.1% | +17.3% | −7.0% | −5.8% | −17.8% | +2.9% | +36.5% | +50.4% | +20.3% | +19.0% | +9.1% | +13.2% | −27.2% | +29.4% | +17.7% | +17.8% | +25.7% | +45.7% | −14.9% | −50.4% | +51.1% | −27.1% | +72.6% | +55.5% |
| SYK Stryker Corporation | 16 of 29 | −1.5% | +21.3% | +23.8% | −7.4% | +10.2% | +18.2% | +35.3% | +2.4% | +30.8% | +30.7% | 0.0% | +27.4% | +39.3% | +12.1% | −6.1% | +7.9% | +26.7% | −46.0% | +36.2% | +24.5% | −7.7% | +13.7% | +26.8% | +15.2% | +15.6% | +45.6% | +26.6% | +47.9% | +25.0% |
| DHR Danaher Corporation | 19 of 29 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% | −11.0% | +72.4% | +35.2% |
| BDX Becton, Dickinson and Company | 12 of 24 | −12.5% | −5.3% | −2.7% | +5.1% | +1.9% | −6.8% | +22.2% | +6.6% | +31.2% | +9.2% | +12.6% | +28.3% | +44.3% | +7.3% | −9.7% | +9.4% | +17.6% | −16.9% | +20.7% | +18.3% | +7.2% | +39.8% | +35.6% | −6.4% | — | — | — | — | — |
| MDT Medtronic Plc | 13 of 29 | +24.0% | +0.3% | +9.6% | −22.6% | −9.8% | +5.7% | +27.3% | +15.2% | +15.3% | −5.4% | +8.6% | +28.1% | +42.8% | +10.6% | +5.8% | −13.8% | +42.6% | −36.3% | −5.2% | −6.3% | +16.8% | +2.7% | +7.3% | −10.3% | −14.8% | +66.4% | −1.5% | +42.1% | +55.3% |
| ICUI ICU Medical, Inc. | 14 of 29 | −8.1% | +55.6% | −36.7% | −33.7% | +10.7% | +14.6% | −18.5% | +6.3% | +46.6% | +30.6% | +37.7% | +28.5% | +4.6% | +35.4% | +23.3% | +0.2% | +10.0% | −8.0% | −11.5% | +3.8% | +43.4% | −20.3% | −8.1% | +25.7% | +47.8% | +97.5% | −30.7% | +77.8% | +57.1% |
| DXCM DexCom, Inc. | 12 of 20 | −14.7% | −37.3% | +9.6% | −15.6% | +45.2% | +69.0% | +82.6% | +109% | −3.9% | −27.1% | +48.8% | +55.5% | +160% | +45.9% | −31.7% | +68.8% | +193% | −68.8% | −10.5% | −33.8% | — | — | — | — | — | — | — | — | — |
| EW Edwards Lifesciences Corporation | 15 of 25 | +15.2% | −2.9% | +2.2% | −42.4% | +42.0% | +17.3% | +52.3% | +35.9% | +20.3% | +18.6% | +24.0% | +93.7% | −27.1% | +27.6% | −12.6% | +86.1% | +58.1% | +19.6% | −2.3% | +13.0% | +0.9% | +37.0% | +18.4% | −7.8% | +55.4% | — | — | — | — |
| PHG Koninklijke Philips N.V. | 12 of 29 | +11.3% | +16.4% | +50.4% | −54.1% | −30.6% | +15.6% | +42.6% | −4.7% | +27.0% | +24.7% | −8.9% | −18.5% | +44.8% | +34.0% | −29.3% | +7.7% | +57.7% | −52.1% | +16.3% | +22.9% | +19.9% | −7.3% | +68.6% | −38.6% | −18.6% | +7.9% | +86.4% | +13.2% | +54.1% |
| BSX Boston Scientific Corporation | 13 of 29 | +6.8% | +54.5% | +24.9% | +8.9% | +18.2% | −20.5% | +28.0% | +42.6% | +14.6% | +17.3% | +39.2% | +10.2% | +110% | +7.3% | −29.5% | −15.9% | +16.3% | −33.5% | −32.3% | −29.8% | −31.1% | −3.3% | +72.9% | +76.3% | +76.3% | −37.5% | −18.4% | +16.9% | −23.5% |
| PODD Insulet Corp. | 10 of 18 | +8.9% | +20.3% | −26.3% | +10.6% | +4.1% | +49.3% | +116% | +15.0% | +83.1% | −0.3% | −17.9% | +24.1% | +74.8% | +12.7% | +21.5% | +8.5% | +85.0% | −67.1% | — | — | — | — | — | — | — | — | — | — | — |
| BAX Baxter International Inc. | 10 of 29 | −33.3% | −22.4% | −21.9% | −39.6% | +8.5% | −3.0% | +28.4% | +2.9% | +47.3% | +17.6% | −2.1% | +8.4% | +7.3% | +38.5% | +0.1% | −11.6% | +11.7% | −6.3% | +26.8% | +24.8% | +10.7% | +15.2% | +11.2% | −46.8% | +22.8% | +56.1% | −0.5% | +30.3% | +26.0% |
| ZBH Zimmer Biomet Holdings, Inc. | 10 of 24 | −14.0% | −12.5% | −3.8% | +4.3% | −17.0% | +3.8% | +45.4% | −13.3% | +17.9% | +1.5% | −8.8% | +22.8% | +41.2% | +26.2% | −0.5% | −9.2% | +46.3% | −38.9% | −15.6% | +16.2% | −15.8% | +13.8% | +69.6% | +35.9% | — | — | — | — | — |
| ALGN Align Technology, Inc. | 12 of 24 | −25.1% | −23.9% | +29.9% | −67.9% | +23.0% | +91.5% | +33.2% | −5.7% | +131% | +46.0% | +17.8% | −2.1% | +106% | +16.9% | +21.4% | +9.7% | +104% | −47.5% | +19.4% | +116% | −39.8% | −34.9% | +498% | −38.7% | — | — | — | — | — |
| TFX Teleflex Incorporated | 12 of 29 | −30.7% | −28.2% | +0.5% | −23.6% | −19.9% | +9.8% | +46.3% | +4.5% | +55.4% | +23.7% | +15.7% | +23.9% | +33.8% | +18.9% | +16.6% | +2.3% | +10.7% | −18.6% | −0.7% | +1.1% | +27.1% | +9.5% | +14.8% | −8.1% | +8.6% | +43.6% | −30.6% | +22.2% | +46.8% |
| GEHC GE HealthCare Technologies Inc. | 1 of 3 | +5.1% | +1.3% | +32.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| COO The Cooper Companies, Inc. | 15 of 29 | −10.8% | −2.8% | +14.5% | −21.0% | +15.4% | +13.2% | +26.4% | +16.9% | +24.7% | +30.6% | −17.1% | +31.1% | +34.2% | +31.6% | +25.6% | +48.6% | +135% | −56.7% | −14.2% | −12.8% | −27.0% | +50.3% | +89.4% | +1.0% | +26.3% | +33.7% | +47.0% | −49.4% | +137% |
| TNDM Tandem Diabetes Care, Inc. | 5 of 12 | −39.0% | +21.8% | −34.2% | −70.1% | +57.3% | +60.5% | +57.0% | +1,509% | −89.0% | −81.8% | −7.0% | −50.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| NVO Novo Nordisk A/S | 17 of 29 | −39.2% | −15.9% | +54.8% | +22.6% | +63.5% | +23.3% | +28.7% | −11.8% | +54.3% | −36.6% | +39.3% | +16.7% | +15.3% | +44.0% | +4.1% | +79.3% | +27.2% | −19.8% | +57.4% | +51.3% | +5.6% | +34.6% | +43.5% | −27.0% | +14.4% | +39.0% | −1.9% | −7.3% | +54.9% |
Risk and diversification
How ABT has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were ABT's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents ABT's five deepest drawdowns since it began trading in 1986, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all four of ABT's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: ABT fell 43.3% from April 1999 to January 2000, while the S&P 500 rose 5.4%.
- The slowest recovery came after ABT fell 45.7% from January to July 2002; it did not regain that peak until August 2006, four years later.
Green means ABT fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | ABT fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| Dot-com bust | −45.7% | −28.9% | Jan 2002 | Jul 2002 | 6 months | Aug 2006 | 4.1 years |
| No named crash | −43.3% | +5.4% | Apr 1999 | Jan 2000 | 9 months | Oct 2000 | 9 months |
| No named crash | −39.6% | +28.5% | Mar 2025 | May 2026 | 14 months | Not yet | — |
| No named crash | −34.6% | — | Mar 1987 | Nov 1987 | 8 months | Jul 1989 | 20 months |
| 2022 bear market | −33.9% | −6.6% | Dec 2021 | Oct 2023 | 22 months | Feb 2025 | 16 months |
How did ABT do in stock market crashes?
This section measures how far ABT, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- ABT fell less than the S&P 500 in seven of the ten crashes it has traded through. The clearest case was the 2008 financial crisis, when ABT fell 22.3% and the S&P 500 fell 55.2%.
- Among its popular alternatives, LLY held up best, falling less than ABT in seven of the ten crashes they both traded through.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than ABT.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT This pageAbbott Laboratories | — | −2.5% | −27.9% | −29.7% | −11.7% | −8.8% | −27.4% | −11.5% | −0.5% | −22.3% | −45.7% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 3 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| LLY Eli Lilly and Company | 7 of 10 | −0.6% | −11.7% | −16.9% | −10.2% | −8.6% | −19.6% | −10.9% | 0.0% | −50.0% | −54.3% |
| TMO Thermo Fisher Scientific Inc. | 4 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| RMD ResMed Inc. | 3 of 10 | −4.1% | −26.6% | −35.3% | −15.1% | −7.6% | −14.4% | −19.4% | −3.1% | −43.8% | −60.0% |
| ISRG Intuitive Surgical, Inc. | 1 of 9 | −2.7% | −47.6% | −40.5% | −24.3% | −8.4% | −14.7% | −20.6% | −3.8% | −75.9% | — |
| JNJ Johnson & Johnson | 7 of 10 | −1.1% | −12.7% | −25.4% | −16.9% | −8.2% | −9.0% | −9.8% | −0.1% | −34.4% | −35.9% |
| CVS CVS Health Corp. | 3 of 10 | −4.4% | −19.9% | −27.3% | −22.1% | −9.2% | −16.9% | −14.2% | −1.1% | −45.3% | −62.4% |
| SYK Stryker Corporation | 3 of 10 | −1.4% | −31.4% | −43.8% | −18.8% | −8.8% | −15.6% | −23.0% | −3.8% | −58.6% | −26.9% |
| DHR Danaher Corporation | 4 of 10 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| BDX Becton, Dickinson and Company | 3 of 9 | −2.0% | −19.7% | −21.8% | −20.4% | −10.8% | −15.1% | −18.3% | −1.6% | −34.1% | — |
| MDT Medtronic Plc | 3 of 10 | −2.1% | −27.9% | −36.0% | −13.8% | −7.2% | −17.6% | −18.0% | −1.5% | −56.5% | −44.2% |
| ICUI ICU Medical, Inc. | 4 of 10 | −1.9% | −43.5% | −26.0% | −24.6% | −6.1% | −29.8% | −16.3% | −4.0% | −43.9% | −38.6% |
| DXCM DexCom, Inc. | 1 of 9 | −4.4% | −48.8% | −36.8% | −27.8% | −5.1% | −47.6% | −33.2% | −6.1% | −87.0% | — |
| EW Edwards Lifesciences Corporation | 2 of 9 | −3.8% | −36.0% | −33.2% | −20.0% | −6.1% | −9.7% | −19.4% | −2.4% | −31.9% | — |
| PHG Koninklijke Philips N.V. | 2 of 10 | −1.4% | −61.7% | −34.5% | −27.0% | −8.4% | −17.8% | −34.1% | −2.5% | −68.3% | −75.2% |
| BSX Boston Scientific Corporation | 4 of 10 | −1.2% | −25.2% | −40.0% | −18.7% | −8.0% | −15.2% | −24.0% | −3.2% | −63.5% | −56.7% |
| PODD Insulet Corp. | 2 of 9 | −2.0% | −33.2% | −39.9% | −31.1% | −4.1% | −37.2% | −36.5% | 0.0% | −89.6% | — |
| BAX Baxter International Inc. | 2 of 10 | −3.6% | −39.1% | −23.0% | −20.9% | −8.7% | −23.0% | −18.6% | −1.9% | −31.6% | −55.7% |
| ZBH Zimmer Biomet Holdings, Inc. | 4 of 9 | 0.0% | −23.9% | −49.6% | −26.0% | −8.2% | −14.8% | −20.3% | −2.1% | −62.0% | — |
| ALGN Align Technology, Inc. | 1 of 9 | −5.9% | −66.8% | −50.3% | −50.7% | −14.2% | −14.1% | −40.6% | −4.3% | −82.6% | — |
| TFX Teleflex Incorporated | 2 of 10 | −2.6% | −47.2% | −42.9% | −16.7% | −8.5% | −10.8% | −21.6% | −0.5% | −42.8% | −29.5% |
| GEHC GE HealthCare Technologies Inc. | 0 of 1 | −2.2% | — | — | — | — | — | — | — | — | — |
| COO The Cooper Companies, Inc. | 2 of 10 | −3.1% | −41.0% | −31.7% | −17.4% | −7.5% | −31.1% | −20.7% | −2.6% | −76.9% | −28.4% |
| TNDM Tandem Diabetes Care, Inc. | 0 of 6 | −8.0% | −69.9% | −47.4% | −40.5% | −19.5% | −46.1% | — | — | — | — |
| NVO Novo Nordisk A/S | 5 of 10 | −1.1% | −21.4% | −23.7% | −13.8% | −3.9% | −20.8% | −23.1% | −1.7% | −40.9% | −51.0% |
How closely does ABT move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares ABT with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- LLY took just 6% of the S&P 500's losses, against 79% for ABT, while still keeping 101% of its gains.
- Over the past 10 years, ABT captured 76% of the S&P 500's gains in rising months and 79% of its losses in falling months, with a beta of 0.64. Its share of the market's losses was slightly larger than its share of the gains.
- Seven of the 23 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than ABT's 0.96, led by LLY, JNJ and RMD.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than ABT's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| ABT This pageAbbott Laboratories | 76% | 79% | 0.96 | 0.64 |
| LLY Eli Lilly and Company | 101% | 6% | 15.73 | 0.37 |
| JNJ Johnson & Johnson | 64% | 53% | 1.20 | 0.46 |
| RMD ResMed Inc. | 91% | 89% | 1.03 | 0.56 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| DXCM DexCom, Inc. | 97% | 97% | 1.00 | 1.13 |
| PODD Insulet Corp. | 81% | 82% | 1.00 | 0.92 |
| ISRG Intuitive Surgical, Inc. | 136% | 154% | 0.88 | 1.28 |
| SYK Stryker Corporation | 82% | 96% | 0.86 | 0.88 |
| NVO Novo Nordisk A/S | 75% | 94% | 0.80 | 0.60 |
| EW Edwards Lifesciences Corporation | 88% | 120% | 0.73 | 0.97 |
| BSX Boston Scientific Corporation | 76% | 109% | 0.70 | 0.72 |
| BDX Becton, Dickinson and Company | 53% | 77% | 0.69 | 0.48 |
| CVS CVS Health Corp. | 59% | 99% | 0.60 | 0.70 |
| MDT Medtronic Plc | 62% | 105% | 0.59 | 0.68 |
| ALGN Align Technology, Inc. | 144% | 243% | 0.59 | 1.70 |
| ICUI ICU Medical, Inc. | 78% | 136% | 0.57 | 0.69 |
| COO The Cooper Companies, Inc. | 78% | 137% | 0.57 | 0.85 |
| PHG Koninklijke Philips N.V. | 75% | 134% | 0.56 | 0.80 |
| TFX Teleflex Incorporated | 79% | 170% | 0.47 | 1.01 |
| ZBH Zimmer Biomet Holdings, Inc. | 62% | 139% | 0.44 | 0.88 |
| BAX Baxter International Inc. | 45% | 125% | 0.36 | 0.64 |
| TNDM Tandem Diabetes Care, Inc. | 35% | 172% | 0.20 | 1.00 |
What diversifies ABT?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with ABT's. Because such investments tend not to fall at the same time, pairing ABT with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in ABT into DXJ would have cut the portfolio's volatility by 17% over the past 5 years and raised its annual return (-1.6% for ABT alone, +4.1% for the mix).
- XLE made money in five of the seven calendar years in which ABT lost money.
- Among large ETFs, DXJ, EMLP and EWP have moved largely independently of ABT over the past 5 years, with correlations of 0.47 or lower, and each still earned a positive 5-year return.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which ABT lost money. The last two columns show a portfolio that is 80% ABT and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2022 | 2016 | 2010 | 2008 | 2005 | 2002 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories (this page) | 1.00 | −8.0% | 0.04 | −20.7% | −12.3% | −8.3% | −2.5% | −13.5% | −26.8% | −24.7% | 23.3% | −1.6% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.19 | +225% | 1.34 | +6.0% | +1.1% | −1.8% | −20.8% | — | — | — | 19.3% | +4.1% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.44 | +101% | 1.04 | +10.4% | +29.8% | — | — | — | — | — | 20.1% | +2.0% |
| EWP Broad MarketiShares MSCI Spain ETF | 0.47 | +140% | 0.97 | −5.2% | −1.8% | −18.8% | −36.8% | +4.6% | −13.6% | −1.5% | 20.7% | +2.9% |
| SMH TechnologyVanEck Semiconductor ETF | -0.01 | +323% | 0.97 | −33.5% | +35.6% | +19.0% | −44.7% | +10.8% | −47.0% | — | 19.8% | +6.7% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.49 | +85.0% | 0.96 | −5.1% | +6.3% | — | — | — | — | — | 19.8% | +1.6% |
| GLD CommoditiesSPDR Gold Shares | 0.22 | +126% | 0.96 | −0.8% | +8.0% | +29.3% | +4.9% | +17.8% | — | — | 19.7% | +2.6% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | 0.22 | +136% | 0.93 | −10.4% | +7.4% | — | — | — | — | — | 20.0% | +3.3% |
| XLE EnergyState Street Energy Select Sector SPDR ETF | 0.21 | +177% | 0.93 | +64.4% | +28.0% | +21.9% | −39.0% | +40.1% | −14.8% | +18.1% | 20.4% | +3.7% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2022 | 2016 | 2010 | 2008 | 2005 | 2002 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories (this page) | 1.00 | −8.0% | 0.04 | −20.7% | −12.3% | −8.3% | −2.5% | −13.5% | −26.8% | −24.7% | 23.3% | −1.6% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.36 | +479% | 1.55 | +54.1% | −17.5% | +21.4% | −39.6% | +18.7% | −8.3% | −36.8% | 21.1% | +5.9% |
| CLS Hardware, Equipment & PartsCelestica Inc. | -0.01 | +3,143% | 1.47 | +1.3% | +7.4% | +2.8% | −20.5% | −25.2% | −65.1% | +350% | 21.9% | +18.2% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.02 | +1,636% | 1.46 | +17.0% | +18.3% | +8.7% | −15.2% | +20.1% | −9.4% | −58.7% | 20.8% | +14.4% |
| MCK Medical - DistributionMcKesson Corporation | 0.39 | +413% | 1.44 | +51.8% | −28.3% | +13.8% | −40.4% | +64.9% | −27.2% | −71.3% | 21.2% | +5.4% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.19 | +690% | 1.41 | +86.6% | +0.7% | — | — | — | — | — | 20.9% | +8.0% |
Common questions
What was ABT's worst drawdown?
ABT's deepest decline since it began trading in 1986 was 45.7%, from January to July 2002. It took about four years from the low to climb back to its old high.
What were ABT's best and worst years?
Over 29 full calendar years, ABT's best year was 2017, when it returned 52.0%. Its worst was 2002, with a return of -26.8%.
Is there a better investment than ABT?
Among ABT's popular alternatives, JNJ earned more than ABT with less volatility over the past 5 years: 12.7% a year at 17.9% volatility, against a loss of 1.7% a year at 23.1%. Looking beyond its popular alternatives, NVS (pharmaceuticals) and TAK (pharmaceuticals) earned more than ABT with less volatility over the past 5 years. NVS returned 17.1% a year at 20.7% volatility, against a loss of 1.7% a year at 23.1%.
Is ABT more volatile than the S&P 500?
Yes. ABT's volatility over the past 5 years was 23.1%, 1.3 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, ABT's return lands within 23.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is ABT's Sharpe ratio?
ABT's Sharpe ratio over the past 5 years was 0.04, against 0.79 for the S&P 500, so ABT earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is ABT with the S&P 500?
Over the past 5 years, ABT's monthly returns had a correlation of 0.39 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against ABT instead: the lower it is, the more that option would diversify a ABT holding.
What are the best alternatives to ABT?
Of the 24 popular alternatives we compared, six outperformed ABT in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: LLY, TMO and RMD.
Did ABT outperform the S&P 500?
ABT finished ahead of the S&P 500 (SPY) in 14 of 29 full calendar years. In 2025, it returned +12.9%, against +17.7% for the index.
How did ABT do in stock market crashes?
ABT fell less than the S&P 500 (SPY) in seven of the ten major crashes it has traded through, and further in three. The clearest case was the 2008 financial crisis, when ABT fell 22.3% and the S&P 500 fell 55.2%.
What diversifies ABT?
These had a low correlation with ABT over the past 5 years and still earned a positive 5-year return: among large ETFs, DXJ (correlation 0.19), EMLP (correlation 0.44) and EWP (correlation 0.47); among large stocks, CAH (correlation 0.36), CLS (correlation -0.01) and FIX (correlation 0.02). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than ABT's. Returns within 0.5 points or 3% of ABT's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.